Rennova Health, Inc. (NASDAQ:RNVA) Files An 8-K Changes in Registrant’s Certifying AccountantItem 4.01. Changes in Registrant’s Certifying Accountant.
(a) Previous Independent Accounting Firm
On September 24, 2018, Rennova Health, Inc. (the “Company”) was informed by Green & Company, CPAs ("Green & Co."), our prior independent registered public accounting firm, that Haynie & Company ("H&C") acquired certain assets of Green & Co. As a result of the acquisition, on September 24, 2018, Green & Co. resigned as the independent public accounting firm of the Company.
The reports of Green & Co. on the Company’s financial statements for the two most recent fiscal years did not contain an adverse opinion or a disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope, or accounting principles, except that the report for each of the years ended December 31, 2017 and December 31, 2016 contained a going concern explanatory paragraph.
During the two most recent fiscal years and through September 24, 2018, (i) there were no disagreements between the Company and Green& Co. on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedures, which disagreements, if not resolved to the satisfaction of Green & Co., would have caused Green & Co. to make reference to the subject matter of the disagreements in its reports on the consolidated financial statements for such years, and (ii) Green & Co. did not advise us of any of the events requiring reporting in this Current Report on Form 8-K under Item 304(a)(1)(v) of Regulation S-K.
The Company provided Green & Co. with a copy of the foregoing disclosures and requested that Green & Co. furnish us with a letter addressed to the Securities and Exchange Commission stating whether or not Green & Co. agrees with the disclosures. A copy of such letter, dated September 28, 2018, is attached as Exhibit 16.1.
(b) New Independent Accounting Firm
Effective September 24, 2018, we engaged H&C to serve as our independent registered public accounting firm for the year ending December 31, 2018. The engagement of H&C was approved by our Audit Committee.
During the Company’s two most recent fiscal years and through September 24, 2018, neither we nor anyone acting on our behalf consulted with H&C regarding either (i) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on our financial statements, and neither a written report nor oral advice was provided to the Company that H&C concluded was an important factor considered by the Company in reaching a decision as to the accounting, auditing or financial reporting issue, or (ii) any matter that was either the subject of a disagreement (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions to Item 304 of Regulation S-K) or a reportable event (as defined in Item 304(a)(1)(v) of Regulation S-K).
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Rennova Health, Inc. ExhibitEX-16.1 2 ex16-1.htm September 28,…To view the full exhibit click here
About Rennova Health, Inc. (NASDAQ:RNVA)
Rennova Health, Inc. (Rennova), formerly CollabRx, Inc., is a provider of diagnostics and supportive software solutions to healthcare providers. The Company operates in three segments: clinical laboratory operations, supportive software solutions, and decision support and informatics operations. The Company is a healthcare enterprise that delivers products and services, including laboratory diagnostics, healthcare technology solutions, and revenue cycle management and intends to provide financial services, to medical providers. Rennova’s principal line of business is clinical laboratory blood and urine testing services. It is also engaged in the provision of urine drug toxicology testing to physicians, clinics and rehabilitation facilities in the United States. Its clinical laboratories include Biohealth Medical Laboratory, Inc.; Alethea Laboratories, Inc.; International Technologies, LLC; EPIC Reference Labs, Inc., and Epinex Diagnostics Laboratories, Inc.
